Drugs / Teprenone

Trials 6 · a red edge is where a trial was stopped

200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT05672134 Apr 2023 → Aug 2024 diastolic heart failure Amsterdam UMC, location VUmc Completed No outcome recorded
Phase 43 trials
Phase 4 NCT01284647 Feb 2011 → Oct 2012 chronic erosive gastritis Changhai Hospital Completed No outcome recorded
Phase 4 NCT01190657 May 2010 → Feb 2013 gastric ulcer, gastritis Eisai Inc. Completed No outcome recorded
Phase 4 NCT00125736 Aug 2005 → Apr 2007 gastric ulcer Eisai Inc. Completed No outcome recorded
Phase not applicable2 trials
NCT07654049 Jun 2026 → Jun 2027 expected digestive system disorder Second Affiliated Hospital, School of Medicine, Zhejiang University Not yet recruiting No outcome recorded
NCT01547559 Jun 2007 → Nov 2014 drug allergy Sun Yat-sen University Unknown No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2/3 NCT01397448 Comparator Jul 2011 → Mar 2013 active peptic ulcer disease Eisai Inc. Completed No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as Teprenone ClinicalTrials.gov intervention name — accepted as the source's own label NCT01547559
3

NCT01284647

NCT07654049

NCT01397448

Known as E0671 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00125736
Known as Geranylgeranylacetone Geranylgeranylacetone protects against small-intestinal injuries induced by diclofenac in patients with rheumatic diseases: a prospective randomized study.” PMID 25660821 Jan 2015
1

NCT05672134

Known as GGA “Geranylgeranylacetone (GGA)” NCT05672134
Known as Selbex ClinicalTrials.gov intervention name — accepted as the source's own label NCT01190657
Known as Teprenona ChEMBL registry synonym — accepted as the source's own label CHEMBL5314356
Route Oral “One 50 mg capsule is orally administered three times daily (150 mg/day)” NCT00125736